Objective: Ranolazine is an anti-ischaemic agent with additional electrophysiological properties by inhibiting the cardiac late Na+ current and reducing the Ca2+ overload; it does not produce a change in heart rate or blood pressure. This study aimed to know if Ranolazine was added to Angiotensin Receptor Blockers plus Mineralocorticoid Receptor Antagonists (ARB+MRA) therapy in hypertensive with normal kidney function can reduce or avoid ventricular extrasystoles without the use of antiarrhythmics drugs such as flecainide or propafenone. Design & Methods: For developing this study, one first group of 45 hypertensive patients was entered, females 17 with an average age of 64.8 (SD 14.0) and males 28 with an average age of 68.4 (SD 12.8) in a regime of ARB+MRA therapy. All patients were assessed with a 24hs-monitoring Holter, pre and post Ranolazine (375/500 mg, 2xd), with an average therapy time-length on females-males by 12.4 (SD 10.0) - 12.8 (SD 12.0) months. Also, the second group of 73 patients was registered, females-males (43–30) with an average age (SD) 67.1 (12.2) - 66.8 (13.5) assessed with a 24hs-monitoring Holter only once at 12.2–16.7 months after ARB+MRA+Ranolazine therapy. All patients achieved normal levels of the central hemodynamic parameters, principally augmentation index (surrogate value of arterial stiffness) and end-systolic pressure measured with applanation tonometry (SphygmoCor System-PVX AtCor-Australia) used according to standard methods. Results: In the pre-and post-treatment group of females-males were observed ventricular extrasystoles a mean of 2610–5004 which were reduced to a mean of 12.5–1464, respectively, with a highly statistically significant difference (p > 0.001). In the post-treatment group, the average of ventricular extrasystoles on females-males was found 15.0–37.4. Interestingly, during ARB+MRA+Ranolazine therapy patients which had not registered anyone ventricular extrasystoles, in the first group were found females-males 8/17 (47%) - 7/28 (25%), and in the second group 14/43 (33%) - 6/30 (20%), respectively. Conclusion: The combination of ARB+MRA therapy normalized the augmentation index and the end-systolic pressure, stabilized the curve volume/pressure reduce the stress of ventricular-arterial coupling, and can avoid the onset of atrial fibrillation, also so it would allow added Ranolazine to perform a beneficial antiarrhythmic action avoiding or reducing the appearance of the ventricular extrasystoles.